Table 3. Sensitivity analysis: Effect of non-progression of cirrhosis stage.
| Mortality | NNS | Relative Risk Reduction | ||||
|---|---|---|---|---|---|---|
| Overall | HCC | Overall | HCC | Overall | HCC | |
| 3 years | 103 | 91 | 12.0% | 36.0% | ||
| No Surveillance | 8.1% | 3.0% | ||||
| Surveillance | 7.1% | 2.0% | ||||
| 5 years | 47 | 42 | 14.6% | 35.9% | ||
| No Surveillance | 14.6% | 6.7% | ||||
| Surveillance | 12.5% | 4.3% | ||||
| 10 years | 22 | 19 | 14.4% | 33.9% | ||
| No Surveillance | 30.9% | 15.8% | ||||
| Surveillance | 26.5% | 10.4% | ||||
| 15 years | 18 | 13 | 12.9% | 32.6% | ||
| No Surveillance | 43.9% | 22.7% | ||||
| Surveillance | 38.3% | 15.3% | ||||
HCC- hepatocellular carcinoma; LTx- liver transplant; NNT- number needed to treat; RFA- radiofrequency ablation
NNS- number needed to be surveillance (in comparison to no surveillance)